Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Abstract 3021: Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158

Xi (Cindy) Chen, Lora Hamuro, Shodeinde Coker, John Hilton, Jennifer R. Diamond, Capucine Baldini, Mark Voskoboynik, Mihaela Cristea, William Edenfield, Kezi Unsal-Kacmaz, Donald Jackson, Abraham Apfel, Ke Xu, Li Zhu, Amit Roy, Akintunde Bello, Ronald Fleming, Paul Statkevich

Cancer Res (2020) 80 (16_Supplement): 3021.

https://doi.org/10.1158/1538-7445.AM2020-3021

Published: 15 August 2020

View article titled, Abstract 3021: Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158

Journal Articles

Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Rui Wang, Xiao Shao, Junying Zheng, Abdel Saci, Max Qian, Irene Pak, Amit Roy, Akintunde Bello, Jasmine Rizzo, Fareeda Hosein, Rebecca A. Moss, Megan Wind-Rotolo, Yan Feng

Cancer Res (2019) 79 (13_Supplement): 2273.

https://doi.org/10.1158/1538-7445.AM2019-2273

Published: 01 July 2019

View article titled, Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Journal Articles

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Xiaochen Zhao, Vijay Ivaturi, Mathangi Gopalakrishnan, Jun Shen, Yan Feng, Paul Statkevich, Eric Richards, Michelle Rashford, Vicki Goodman, Joga Gobburu, Akintunde Bello, Amit Roy, Shruti Agrawal

Cancer Res (2017) 77 (13_Supplement): CT101.

https://doi.org/10.1158/1538-7445.AM2017-CT101

Published: 01 July 2017

View article titled, Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Journal Articles

Abstract CT128: Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab

Yan Feng, Manish Gupta, Shruti Agrawal, Amit Roy

Cancer Res (2015) 75 (15_Supplement): CT128.

https://doi.org/10.1158/1538-7445.AM2015-CT128

Published: 01 August 2015

View article titled, Abstract CT128: Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab

Journal Articles

Betulinic Acid, a Catalytic Inhibitor of Topoisomerase I, Inhibits Reactive Oxygen Species–Mediated Apoptotic Topoisomerase I–DNA Cleavable Complex Formation in Prostate Cancer Cells but Does Not Affect the Process of Cell Death

Agneyo Ganguly, Benubrata Das, Amit Roy, Nilkantha Sen, Somdeb Bose Dasgupta, Sibabrata Mukhopadhayay, Hemanta K. Majumder

Cancer Res (2007) 67 (24): 11848–11858.

https://doi.org/10.1158/0008-5472.CAN-07-1615

Published: 18 December 2007

View article titled, Betulinic Acid, a Catalytic Inhibitor of Topoisomerase I, Inhibits Reactive Oxygen Species–Mediated Apoptotic Topoisomerase I–DNA Cleavable Complex Formation in Prostate Cancer Cells but Does Not Affect the Process of Cell Death

NARROW

Abstract 3021: Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158

Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Abstract CT128: Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab

Betulinic Acid, a Catalytic Inhibitor of Topoisomerase I, Inhibits Reactive Oxygen Species–Mediated Apoptotic Topoisomerase I–DNA Cleavable Complex Formation in Prostate Cancer Cells but Does Not Affect the Process of Cell Death

Email alerts

AACR Journals

Abstract 3021: Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for the BET inhibitor BMS-986158

Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Abstract CT128: Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab

Betulinic Acid, a Catalytic Inhibitor of Topoisomerase I, Inhibits Reactive Oxygen Species–Mediated Apoptotic Topoisomerase I–DNA Cleavable Complex Formation in Prostate Cancer Cells but Does Not Affect the Process of Cell Death

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only